💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tocilizumab

CHEMBL1237022 Phase 4 अनुमोदित Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This biologic medication blocks the action of interleukin-6 (IL-6), an immune protein that drives inflammation, and is used to treat rheumatoid arthritis, certain forms of juvenile arthritis, giant cell arteritis, and severe cytokine release syndrome (including that caused by COVID-19 or CAR-T cell therapy). It is given either as an intravenous infusion or a subcutaneous injection. Patients need regular monitoring for infections, liver function, and blood counts.

चिकित्सीय क्षेत्र

अग्नाशय कैंसर अनिद्रा अस्थमा उच्च रक्तचाप ओवेरियन कैंसर कोलोरेक्टल कैंसर क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर थायरॉइड कैंसर दर्द प्रबंधन दीर्घकालिक दर्द नॉन-स्मॉल सेल लंग कैंसर प्रोस्टेट कैंसर मिर्गी (एपिलेप्सी) मूत्राशय कैंसर मेजर डिप्रेसिव डिसऑर्डर मेलानोमा मोटापा रुमेटॉइड आर्थराइटिस रुमेटोलॉजी लिम्फोमा ल्यूकेमिया सिज़ोफ्रेनिया सिस्टेमिक ल्यूपस एरिथेमेटोसस स्ट्रोक स्तन कैंसर हृदय विफलता हृदय-संवहनी रोग

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

This biologic medication blocks the action of interleukin-6 (IL-6), an immune protein that drives inflammation, and is used to treat rheumatoid arthritis, certain forms of juvenile arthritis, giant cell arteritis, and severe cytokine release syndrome (including that caused by COVID-19 or CAR-T cell therapy). It is given either as an intravenous infusion or a subcutaneous injection. Patients need regular monitoring for infections, liver function, and blood counts.

Yes, Tocilizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1237022. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.